Rhythm Pharmaceuticals (RYTM) announced that the United Kingdoms Medicines & Healthcare products Regulatory Agency or MHRA has expanded the marketing authorization for IMCIVREE or setmelanotide to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome or genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, deficiency or biallelic leptin receptor deficiencyin adult and pediatric patients as young as 2 years old and older.
IMCIVREE initially received marketing authorization from the MHRA as an option for treating obesity and control of hunger in patients aged 6 years and older in these indications in 2022. A supplemental New Drug Application for IMCIVREE for patients as young as 2 years of age is currently under priority review with the FDA, with an assigned PDUFA goal date of December 26, 2024.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.